Response to Tsuda et al. "demonstrating the undermining of science and health policy after the Fukushima nuclear accident by applying the toolkit for detecting misused epidemiological methods".

Epidemiological methods Nuclear accident Overdiagnosis Screening Thyroid cancer

Journal

Environmental health : a global access science source
ISSN: 1476-069X
Titre abrégé: Environ Health
Pays: England
ID NLM: 101147645

Informations de publication

Date de publication:
17 02 2023
Historique:
received: 05 01 2023
accepted: 14 01 2023
entrez: 21 2 2023
pubmed: 22 2 2023
medline: 25 2 2023
Statut: epublish

Résumé

The SHAMISEN (Nuclear Emergency Situations - Improvement of Medical And Health Surveillance) European project was conducted in 2015-2017 to review the lessons learned from the experience of past nuclear accidents and develop recommendations for preparedness and health surveillance of populations affected by a nuclear accident. Using a toolkit approach, Tsuda et al. recently published a critical review of the article by Cléro et al. derived from the SHAMISEN project on thyroid cancer screening after nuclear accident. We address the main points of criticism of our publication on the SHAMISEN European project. We disagree with some of the arguments and criticisms mentioned by Tsuda et al. We continue to support the conclusions and recommendations of the SHAMISEN consortium, including the recommendation not to launch a mass thyroid cancer screening after a nuclear accident, but rather to make it available (with appropriate information counselling) to those who request it.

Sections du résumé

BACKGROUND
The SHAMISEN (Nuclear Emergency Situations - Improvement of Medical And Health Surveillance) European project was conducted in 2015-2017 to review the lessons learned from the experience of past nuclear accidents and develop recommendations for preparedness and health surveillance of populations affected by a nuclear accident. Using a toolkit approach, Tsuda et al. recently published a critical review of the article by Cléro et al. derived from the SHAMISEN project on thyroid cancer screening after nuclear accident.
MAIN BODY
We address the main points of criticism of our publication on the SHAMISEN European project.
CONCLUSION
We disagree with some of the arguments and criticisms mentioned by Tsuda et al. We continue to support the conclusions and recommendations of the SHAMISEN consortium, including the recommendation not to launch a mass thyroid cancer screening after a nuclear accident, but rather to make it available (with appropriate information counselling) to those who request it.

Identifiants

pubmed: 36803161
doi: 10.1186/s12940-023-00966-z
pii: 10.1186/s12940-023-00966-z
pmc: PMC9936769
doi:

Types de publication

Review Letter Comment

Langues

eng

Sous-ensembles de citation

IM

Pagination

17

Commentaires et corrections

Type : CommentOn

Informations de copyright

© 2023. The Author(s).

Références

Epidemiology. 2016 May;27(3):316-22
pubmed: 26441345
Epidemiology. 2016 May;27(3):e17
pubmed: 26841060
Environ Int. 2021 Jan;146:106230
pubmed: 33171378
Environ Int. 2021 Jan;146:106200
pubmed: 33197788
Environ Health. 2022 Aug 24;21(1):77
pubmed: 36002833
Lancet Diabetes Endocrinol. 2021 Mar;9(3):144-152
pubmed: 33482107
Annu Rev Public Health. 1995;16:61-81
pubmed: 7639884

Auteurs

Enora Cléro (E)

Health and Environment Division, Institute for Radiological Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, France.

Claire Demoury (C)

Risk and Health Impact Assessment Unit, Sciensano, Brussels, Belgium.

Bernd Grosche (B)

Retired Federal Office for Radiation Protection (BfS), Munich, Germany.

Liudmila Liutsko (L)

Institute for Global Health (ISGlobal), Barcelona, Spain.
Pompeu Fabra University (UPF), Barcelona, Spain.
Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain.
Unitat de Suport a la Recerca Metropolitana Nord, IDIAP Jordi Gol, Barcelona, Spain.

Yvon Motreff (Y)

Santé publique France, F-94415, Saint-Maurice, France.

Takashi Ohba (T)

Fukushima Medical University, 1 Hikarigaoka, Fukushima, Fukushima, 9601295, Japan.

Deborah Oughton (D)

Norwegian University of Life Sciences (NMBU), Center for Environmental Radioactivity (CERAD), Aas, Norway.

Philippe Pirard (P)

Santé publique France, F-94415, Saint-Maurice, France.

Agnès Rogel (A)

Santé publique France, F-94415, Saint-Maurice, France.

Thierry Schneider (T)

Nuclear Protection Evaluation Centre (CEPN), Fontenay-aux-Roses, France.

An Van Nieuwenhuyse (A)

Centre for Environment and Health, Department of Public Health and Primary Care, Leuven, Belgium.
Department of Health Protection, Laboratoire National de Santé (LNS), Dudelange, Luxembourg.

Dominique Laurier (D)

Health and Environment Division, Institute for Radiological Protection and Nuclear Safety (IRSN), Fontenay-aux-Roses, France.

Elisabeth Cardis (E)

Institute for Global Health (ISGlobal), Barcelona, Spain. elisabeth.cardis@isglobal.org.
Pompeu Fabra University (UPF), Barcelona, Spain. elisabeth.cardis@isglobal.org.
Spanish Consortium for Research and Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain. elisabeth.cardis@isglobal.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH